Pricing Log in Create free account

Alumis Inc. (ALMS) vs ArriVent BioPharma, Inc. (AVBP)

Alumis Inc. and ArriVent BioPharma, Inc. are both Biotechnology companies. Alumis Inc. and ArriVent BioPharma, Inc. are of similar size ($842.4M and $827.9M). ArriVent BioPharma, Inc. has the higher net margin (0.00% vs −5,933.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, ArriVent BioPharma, Inc. leads on 8 and Alumis Inc. on 3.

Valuation

Metric ALMS AVBP Biotechnology median
P/E n/m n/m 8.50
P/S 105.63 n/m 9.71
P/B 1.73 2.16 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 37.74 n/m 9.21
Earnings yield (63.07%) (21.73%) (33.15%)
Free cash flow yield (45.02%) (18.65%) (25.50%)

Profitability

Metric ALMS AVBP Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (6,204.39%) 0.00% 0.00%
Net margin (5,933.45%) 0.00% 0.00%
Free cash flow margin (4,755.33%) 0.00% 0.00%
Return on equity (93.65%) (53.10%) (56.36%)
Return on assets (74.94%) (49.30%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALMS AVBP Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 72.45% (68.75%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALMS AVBP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.74 14.16 4.72
Net debt to EBITDA 0.69 1.73 0.96

Dividend

Metric ALMS AVBP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALMS AVBP Biotechnology median
Market cap 842.35m 827.88m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack